ACTs for the treatment of schistosomiasis

The Lancet Infectious Diseases

Volumn 11, Issue 7, 2011, Pages 498-

  Fortin, Anny ^a   Jansen, Frans Herwig ^a  

^a Dafra Pharma International   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ; ARTESUNATE; PRAZIQUANTEL; PYRIMETHAMINE; SULFALENE;

DRUG EFFECT; DRUG EFFICACY; FOLLOW UP; FUNDING; HUMAN; LETTER; MALARIA; NONHUMAN; PRIORITY JOURNAL; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS;

ANIMALS; ANTHELMINTICS; ARTEMISININS; HUMANS; PYRIMETHAMINE; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; SULFALENE;

EID: 79959299464     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70157-8     Document Type: Letter

References (3)

1. Obonyo CO, Muok EMO, Mwinzi PNM Efficacy of artesunate with sulfalene plus pyrimethamine versus praziquantel for treatment of Schistosoma mansoni in Kenyan children: an open-label randomised controlled trial. Lancet Infect Dis 2010, 10:603-611.
2. Sissoko MS, Dabo A, Traore H, et al. Efficacy of artesunate + sulfamethoxypyrazine/pyrimethamine versus praziquantel in the treatment of Schistosoma haematobium in children. PLoS One 2009, 4:e6732.
3. Utzinger J, Tanner M, Keiser J ACTs for schistosomiasis: do they act?. Lancet Infect Dis 2010, 10:579-581.